Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive disease with no known cure.
It is a neurodegenerative disease, where inflammation and oxidative stress result in the death of neurons.
The current treatments do not cure the disease, they only provide a moderate improvement in the symptoms.
Cannabinoids and terpenes have repeatedly demonstrated their anti-oxidative, anti-inflammatory, and neuroprotective properties.
Based on in silico studies and published scientific research, we are creating a combination of non-psychoactive cannabinoids.
This combination should* provide substantial relief from the ALS symptoms while slowing disease progression.
This cannabinoid formulation will provide a more effective solution to the current cannabinoid-based drugs, tackling issues of Delta-9-tetrahydrocannabinol (THC); tolerance, bioavailability, and negative side effects.
Many ALS patients are using cannabis to gain relief from their symptoms, but cannabis is only legally available in certain states and regions.
If this product is bought to the market as a pharmaceutical drug, it will be available in every region regardless of cannabis legislation.
(*This product is still at the preclinical stage, as a result currently there is not yet clinical evidence of its effectiveness.)
ALS patients deserve a tailored made prescription cannabis-based medicine that is safe and effective.
The development of a safe, efficient optimized cannabinoid formulation, will allow clinical testing in humans and enable final marketing approval as a pharmaceutical drug.
For further information on ALS, check out the following websites;
https://www.ninds.nih.gov/amyotrophic-lateral-sclerosis-als-fact-sheet
https://www.alsuntangled.com/review/cannabis/
https://www.als.ca/wp-content/uploads/2020/12/Fact-Sheet-Cannabis-and-ALS_FINAL.pdf